September 28, 2020
This morning Abbott announced that its continuous glucose monitor the FreeStyle Libre 3 earned a CE mark, making it cleared for use for individuals with diabetes living in the European Union. This news comes just a few months after the company landed the much-awaited U.S. FDA clearance for its FreeStyle Libre 2.
Like its predecessor this monitor can also last for 14 days and transmit glucose data...
September 21, 2020
Abbott announced that its Libre Sense Glucose Sport Biosensor has achieved a CE Mark, paving the way for a European roll-out.
The Libre Sense biosensor provides continuous glucose monitoring (CGM) to help athletes understand the efficacy of their nutrition choices on training and competition.
Based on Abbott's FreeStyle Libre technology for people living with diabetes, it is the first personal-...
September 2, 2020
Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and available to Medicare beneficiaries with diabetes who meet eligibility criteria.
Indicated for diabetes management in patients aged four years or older, the updated version of Abbott's system can...
August 31, 2020
Hogwash, or a brain activity breakthrough? Friday evening came with a long-awaited look at the work of Neuralink, Elon Musk's ambitious brain-computer interface implant startup. In the streamed progress update, Musk ran down a PowerPoint overview of the technology's capabilities, which he likened to "a Fitbit in your skull." The coin-shaped implant will read and wirelessly transmit brain signals...
August 27, 2020
Abbott has scored yet another Emergency Use Authorization for rapid coronavirus testing – this one, named BinaxNOW COVID-19 Ag Card, come in the form of a card and can provide results in 15 minutes.
The other notable difference in this test is the price point. Abbott said it will sell the tests for $5 each.
Users will also be able to link their results to Abbott’s app dubbed NAVICA, which will...
August 7, 2020
Shortly before news broke that Teladoc was set to acquire Livongo, the chronic disease management company announced its quarterly earnings results. On Aug. 5 it announced that its second quarter total revenue came in at $91.9 million, which was up 125% YoY. The company reported a GAAP gross margin of 76.6% and non-GAAP gross margin of 77.3%.
The company attributed the gains to its growing...
July 24, 2020
Abbott has received FDA approval for a neuromodulation system-controller app that runs on iOS devices, the company announced Thursday.
Compatible with Abbott's broader NeuroSphere Digital Care platform, the Patient Controller app replaces the separate device patients use to adjust the company's neuromodulation products. These include the Infinity DBS System for Parkinson's disease or essential...
July 6, 2020
Abbott’s Bluetooth connected cardioverter defibrillator and cardiac resynchronization therapy defibrillator, part of the Gallant product line, scored FDA clearance this morning.
Patients using the technology can connect it to a smartphone app, called MyMerlinPulse, which will let both patients and providers see transmission history and device performance. The app is also designed to nudge...
July 1, 2020
Walgreens Boots Alliance expanded its partnership with Microsoft and Adobe to launch a digital platform that will deliver personalized healthcare and shopping offerings. It will give Walgreens and Boots customers the ability to access products and services from its pharmacy and retail businesses wherever and whenever they want. This marks WBA’s second phase of its digital transformation.
June 15, 2020
This morning Abbott revealed that its much anticipated integrated continuous glucose monitoring system the FreeStyle Libre 2 is now FDA cleared for adults and kids over the age of 4 with diabetes.
The latest product is able to continuously transmit glucose data every minute, and users can set the system to send alarms when their glucose is too high or too low. Previously users had to scan the...